Aim. In this study, we compared the efficacy of sucralfate suspension with chlorhexidine as an oral rinse in patients with recurrent aphthous stomatitis (RAS) in terms of pain relief and healing time. Materials and Methods. The subjects with a complaint of recurrent oral aphthous ulcers less than 1？cm in diameter on the first day of the occurrence of the ulcer and between 20 and 40 years were included in the study. Seventy patients completed the study. The patients were randomized into two groups as SCH group and CHX group. Changes in pain scores, healing time, and side effects of the treatments were evaluated. Results. The mean value of pain scores on the days after the treatment from the first day to the seventh day was significantly higher in CHX group than SCH group ( ). On the seventh day after the treatment, the ulcers were completely reepithelialized in 23 patients in SCH group and in 19 patients in CHX group. The difference was statistically significant ( ). In SCH group, the mean healing time of ulcers was days whereas it was days in CHX group. The difference was statistically significant ( ). No side effects were recorded in either of the groups. Conclusion. Topical sucralfate suspension is an easy, safe, inexpensive, and effective treatment option for RAS to obtain pain relief and shorten the healing time of oral ulcers. 1. Introduction Recurrent aphthous stomatitis (RAS) is a disease which presents as recurrent, round, shallow oral ulcerations surrounded by inflammation characterized by a break in the mucous membrane [1]. RAS is one of the most common diseases of the oral mucosa affecting 20% of the general population [2]. RAS is classified into 3 types according to the diameter of the lesion, namely, the minor, major, and herpetiform aphthous ulcerations. The most common form of RAS is minor aphthous ulcerations, and the minor form is, respectively, followed by major and herpetiform ulcerations [3]. The etiology of RAS still remains unknown. These ulcerations may be indicative of underlying systemic diseases ranging from vitamin deficiency to autoimmunity [4]. Pain is the obvious characteristic of the aphthous ulcerations causing difficulty in eating, swallowing, and speaking. To control the pain, a number of different treatment options exist including steroids, analgesics, topical anesthetics agents (lidocaine, polidocanol, benzocaine, and tetracaine), antiseptics and anti-inflammatory agents (chamomile extract solution, chlorhexidine, triclosan, and diclofenac 3% in hyaluronan), tetracycline suspension, sucralfate suspension, silver
References
[1]
J. M. Casiglia, “Recurrent stomatitis: diagnosis, and treatment,” General Dentistry, vol. 50, pp. 157–166, 2002.
[2]
J. D. Shulman, “Prevalence of oral mucosal lesions in children and youths in the USA,” International Journal of Paediatric Dentistry, vol. 15, no. 2, pp. 89–97, 2005.
[3]
J. V. Bagan, J. M. Sanchis, M. A. Milian, M. Penarrocha, and F. J. Silvestre, “Recurrent aphthous stomatitis. A study of the clinical characteristics of lesions in 93 cases,” Journal of Oral Pathology and Medicine, vol. 20, no. 8, pp. 395–397, 1991.
[4]
M. S. Greenberg and A. Pinto, “Etiology and management of recurrent aphthous stomatitis,” Current Infectious Disease Reports, vol. 5, no. 3, pp. 194–198, 2003.
[5]
A. Altenburg and C. C. Zouboulis, “Current concepts in the treatment of recurrent aphthous stomatitis,” Skin therapy letter, vol. 13, no. 7, pp. 1–4, 2008.
[6]
A. C. Thompson, A. Nolan, and P.-J. Lamey, “Minor aphthous oral ulceration: a double-blind cross-over study of beclomethasone dipropionate aerosol spray,” Scottish Medical Journal, vol. 34, no. 5, pp. 531–532, 1989.
[7]
M. A. Gonzalez-Moles, P. Morales, A. Rodriguez-Archilla, I. R. Isabel, and S. Gonzalez-Moles, “Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, vol. 93, no. 3, pp. 264–270, 2002.
[8]
L. L. Muzio, A. della Valle, M. D. Mignogna et al., “The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propionate in three preparations: a clinical and pilot study on 54 patients,” Journal of Oral Pathology and Medicine, vol. 30, no. 10, pp. 611–617, 2001.
[9]
R. W. Matthews, C. M. Scully, B. G. H. Levers, and W. S. Hislop, “Clinical evaluation of benzydamine, chlorhexidine, and placebo mouthwashes in the management of recurrent aphthous stomatitis,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, vol. 63, no. 2, pp. 189–191, 1987.
[10]
G. Soylu ？zler, “Silver nitrate cauterization: a treatment option for aphthous stomatitis,” Journal of Cranio-Maxillofacial Surgery, vol. 42, no. 5, pp. 281–283, 2014.
[11]
W. R. Garnett, “Sucralfate: alternative therapy for peptic-ulcer disease,” Clinical Pharmacy, vol. 1, pp. 1307–1314, 1982.
[12]
W. D. Rees, “Mechanisms of gastroduodenal protection by sucralfate,” The American Journal of Medicine, vol. 91, no. 2, pp. 58–63, 1991.
[13]
S. J. Konturek, T. Brzozowski, J. Majka, and K. Czarnobilski, “Role of nitric oxide and prostaglandins in sucralfate-induced gastroprotection,” European Journal of Pharmacology, vol. 211, no. 2, pp. 277–279, 1992.
[14]
O. M. Laudanno, O. A. Bedini, J. A. Cesolari, and P. San Miguel, “Evidence of anti-oxidant role of sucralfate in gastric mucosal protection,” Italian Journal of Gastroenterology, vol. 22, no. 1, pp. 19–21, 1990.
[15]
G. Campisi, F. Spadari, and A. Salvato, “Sucralfate in odontostomatology: clinical experience,” Minerva Stomatologica, vol. 46, no. 6, pp. 297–305, 1997.
[16]
M. Cengiz, E. ？zyar, D. ？ztürk, F. Akyol, I. L. Atahan, and M. Hayran, “Sucralfate in the prevention of radiation-induced oral mucositis,” Journal of Clinical Gastroenterology, vol. 28, no. 1, pp. 40–43, 1999.
[17]
D. Etiz, H. ？. Erkal, M. Serin et al., “Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies,” Oral Oncology, vol. 36, no. 1, pp. 116–120, 2000.
[18]
P. Pfeiffer, E. L. Madsen, O. Hansen, and O. May, “Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study,” Acta Oncologica, vol. 29, no. 2, pp. 171–173, 1990.
[19]
J. Rattan, M. Schneider, N. Arber, M. Gorsky, and D. Dayan, “Sucralfate suspension as a treatment of recurrent aphthous stomatitis,” Journal of Internal Medicine, vol. 236, no. 3, pp. 341–343, 1994.
[20]
E. Alpsoy, H. Er, C. Durusoy, and E. Yilmaz, “The use of sucralfate suspension in the treatment of oral and genital ulceration of Behcet disease: a randomized, placebo-controlled, double-blind study,” Archives of Dermatology, vol. 135, no. 5, pp. 529–532, 1999.
